COCP - コクリスタル・ファ―マ (Cocrystal Pharma Inc.) コクリスタル・ファ―マ

 COCPのチャート


 COCPの企業情報

symbol COCP
会社名 Cocrystal Pharma Inc (コクリスタル・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Cocrystal Pharma Inc. is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.   コクリスタル・ファ―マは米国の医薬品企業。主にヒトのウィルス性疾患の治療薬の開発に従事する。ウィルスの複製機能を阻害する抗ウィルス治療薬で、RNAポリメラ―ゼ酵素、ヘリカ―ゼ酵素、C型肝炎のNS5Aたんぱく質、インフルエンザウィルスやノロウィルスのRNAポリメラ―ゼを含む。同社は薬物レベルでの酵素相互作用に焦点を当てる。本社はジョ―ジア州タッカ―。   Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
本社所在地 1860 Montreal Road Tucker GA 30084 USA
代表者氏名 Raymond F. Schinazi レイモンドF.シナジー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 425-398-7178
設立年月日 39052
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 10人
url https://www.cocrystalpharma.com/
nasdaq_url https://www.nasdaq.com/symbol/cocp
adr_tso
EBITDA EBITDA(百万ドル) -8.06300
終値(lastsale) 2.725
時価総額(marketcap) 81540382.1
時価総額 時価総額(百万ドル) 81.98923
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 75.14823
当期純利益 当期純利益(百万ドル) 0.04100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cocrystal Pharma Inc revenues was not reported. Net loss decreased 18% to $2.9M. Lower net loss reflects Research and development decrease of 40% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.11.

 COCPのテクニカル分析


 COCPのニュース

   Cocrystal Pharma added to Russell Microcap Index  2021/06/28 13:28:10 Seeking Alpha
   Cocrystal Joins Russell Microcap® Index  2021/06/28 12:00:00 Intrado Digital Media
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap ® Index after the U.S. market opens today, June 28, 2021.
   Cocrystal Joins Russell Microcap Index  2021/06/28 12:00:00 Wallstreet:Online
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap Index after
   Cocrystal Pharma plans to initiate a phase 1 trial of CC-42344 in Q3 2021  2021/06/23 12:13:41 Seeking Alpha
   Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter  2021/06/23 12:00:00 Intrado Digital Media
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021.
   Why Cocrystal Pharma, Precision BioScience Are Trading Higher Today  2021/01/19 17:18:23 Benzinga
Cocrystal Pharma (NASDAQ: COCP ) shares are trading higher after the company announced … Full story available on Benzinga.com
   Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference  2021/01/05 08:00:00 Benzinga
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical-stage biotechnology …
   72 Biggest Movers From Wednesday  2020/11/27 10:01:25 Benzinga
Gainers AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) shares jumped 104% to close at $7.14 on Wednesday after the company issued strong sales forecast for FY20. Newborn Acquisition Corp. (NASDAQ: NBAC ) jumped 86.2% to close at $22.27 after gaining around 8% on Tuesday. Mmtec, Inc. (NASDAQ: MTC ) jumped 67.5% to close at $2.01 on Wednesday after climbing over 11% on Tuesday. Future FinTech Group Inc. (NASDAQ: FTFT ) gained 40.2% to close at $3.00. Slack Technologies, Inc. (NYSE: WORK ) climbed 37.6% to close at $40.70 following reports indicating Salesforce has held M&A talks with the company. Fisker Inc. (NYSE: FSR ) rose 35.3% to close at $21.61 after Citigroup initiated coverage on the stock with a Buy rating and a price target of $26 per share. Appian Corporation (NASDAQ: APPN ) jumped 31.7% to close at $174.90. Renalytix AI PLC (NASDAQ: RNLX ) jumped 31.7% to close at $14.08 after the company's Kantaro Biosciences joint venture received FDA Emergency Use Authorization for its COVID-SeroKlir antibody test kit.
   50 Stocks Moving In Wednesday's Mid-Day Session - Stocks News Feed  2020/11/25 18:37:32 Stocks News Feed
Gainers AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC) shares climbed 99.7% to $6.99 after the company issued strong sales forecast for FY20. Mmtec, Inc. (NASDAQ: MTC) climbed 82.2% to $2.20 after climbing over 11% on Tuesday. Newborn Acquisition Corp. (NASDAQ: NBAC) climbed 56.4% to $18.70 after gaining around 8% on Tuesday. Cocrystal Pharma,… Read More »50 Stocks Moving In Wednesday’s Mid-Day Session
   Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biotech Stock  2020/11/25 14:31:51 InvestorPlace
Cocrystal Pharma (COCP) is on the move Wednesday even with there being a lack of news concerning the pharmaceutical company.

 関連キーワード  (医薬品 米国株 コクリスタル・ファ―マ COCP Cocrystal Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)